Research
Molecular
Aberrant activation of SCD1 contributes to obesity, non-alcoholic fatty liver, diabetes, and cancer.
Targeting SCD1 may help in managing these metabolic diseases.
StrongSupportsmedium confidence
Aberrant transcriptional and epigenetic activation of SCD1...promoting the progression of obesity, non-alcoholic fatty liver, diabetes and cancer.
Why this rating
The abstract provides a clear link between SCD1 and multiple diseases.
Source
SCD1 is the critical signaling hub to mediate metabolic diseases: Mechanism and the development of its inhibitors
Qin Sun et al. · Biomedicine & Pharmacotherapy · 2023
reviewCited 101×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →